EcoDrugPlus

Tyrosine-Protein Kinase Lyn

Ensembl ID : ENSMZEG00005014385
Gene Symbol: LOC101477890
3 Cross references
195 Possible Orthologues:

Tyrosine-Protein Kinase Fyna

Ensembl ID : ENSMZEG00005001875
Gene Symbol: LOC101474799
3 Cross references
191 Possible Orthologues:

Tyrosine-Protein Kinase Yes

Ensembl ID : ENSMZEG00005020115
Gene Symbol: LOC101479012
3 Cross references
206 Possible Orthologues:

Uncharacterized Loc101466819

Ensembl ID : ENSMZEG00005024182
Gene Symbol: LOC101466819
3 Cross references
154 Possible Orthologues:

Uncharacterized Loc101477305

Ensembl ID : ENSMZEG00005006453
Gene Symbol: LOC101477305
2 Cross references
196 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSMZEG00005019357
Gene Symbol: UTS2R
4 Cross references
97 Possible Orthologues:

Utrophin

Ensembl ID : ENSMZEG00005017614
Gene Symbol: UTRN
4 Cross references
270 Possible Orthologues:

Vascular Endothelial Growth Factor A

Ensembl ID : ENSMZEG00005014953
Gene Symbol: VEGFA
3 Cross references
201 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSMZEG00005021878
Gene Symbol: VDR
3 Cross references
388 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSMZEG00005026978
Gene Symbol: LOC101467549
3 Cross references
392 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1

Ensembl ID : ENSMZEG00005012961
Gene Symbol: LOC101466626
3 Cross references
190 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1d

Ensembl ID : ENSMZEG00005026771
Gene Symbol: LOC101480057
3 Cross references
177 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).